Johnson & Johnson (NYSE:JNJ) Shares Down 0.1%

Johnson & Johnson (NYSE:JNJ)’s share price was down 0.1% during trading on Monday . The company traded as low as $146.31 and last traded at $146.38. Approximately 865,642 shares changed hands during mid-day trading, a decline of 88% from the average daily volume of 7,283,921 shares. The stock had previously closed at $146.48.

Wall Street Analyst Weigh In

A number of analysts recently commented on JNJ shares. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their target price for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Morgan Stanley decreased their target price on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Monday, July 1st. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Sunday, June 30th. Finally, Bank of America decreased their price objective on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $174.07.

Johnson & Johnson Trading Up 1.6 %

The company has a market capitalization of $359.58 billion, a P/E ratio of 9.22, a price-to-earnings-growth ratio of 2.42 and a beta of 0.52. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. The firm has a fifty day moving average price of $147.96 and a 200-day moving average price of $153.59.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. Johnson & Johnson’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the company posted $2.68 earnings per share. On average, equities research analysts anticipate that Johnson & Johnson will post 10.62 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were paid a $1.24 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend was Monday, May 20th. This represents a $4.96 annualized dividend and a yield of 3.32%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Hedge Funds Weigh In On Johnson & Johnson

Several institutional investors have recently bought and sold shares of the company. Csenge Advisory Group lifted its stake in Johnson & Johnson by 5.0% in the second quarter. Csenge Advisory Group now owns 22,875 shares of the company’s stock valued at $3,343,000 after purchasing an additional 1,090 shares during the last quarter. Advocate Group LLC lifted its position in shares of Johnson & Johnson by 1.0% during the second quarter. Advocate Group LLC now owns 56,773 shares of the company’s stock worth $8,298,000 after acquiring an additional 588 shares in the last quarter. Founders Capital Management lifted its position in shares of Johnson & Johnson by 88.7% during the second quarter. Founders Capital Management now owns 35,375 shares of the company’s stock worth $5,170,000 after acquiring an additional 16,631 shares in the last quarter. Richard P Slaughter Associates Inc lifted its position in shares of Johnson & Johnson by 20.7% during the second quarter. Richard P Slaughter Associates Inc now owns 11,162 shares of the company’s stock worth $1,631,000 after acquiring an additional 1,916 shares in the last quarter. Finally, Simplicity Wealth LLC lifted its position in shares of Johnson & Johnson by 0.3% during the second quarter. Simplicity Wealth LLC now owns 130,007 shares of the company’s stock worth $19,002,000 after acquiring an additional 424 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.